Who we are
CuraVac is a clinical-stage biotechnology company developing Therapeutic Vaccines and Active Targeted Immunotherapies for autoimmune diseases.
With the use of a new revolutionary technique based on complementary peptides, we aim to induce long-term immunity against autoimmune diseases such as Multiple Sclerosis (MS), Myasthenia Gravis (MG), Type 1 diabetes, Graves’ disease, Systemic Lupus Erythematosus (SLE) and Hashimoto’s disease.
CuraVac’s CV-MG is a potential breakthrough in MG treatments and a potential therapeutic revolution for all autoimmune diseases – being the first to possibly bring a long-lasting improvement and a potential cure to patients.
Autoimmune diseases in the U.S.
The CuraVac team is composed of 3 key people at the center of a collaborative network of the highest quality from the industry and the academic world: Dr. Stéphane Huberty, Professor J. Edwin Blalock and Nicolas Havelange.
Following a Clinical Trial Authorization received in November 2015, 24 patients received three injections of the MG therapeutic vaccine in a phase 1B clinical trial that took place at the Antwerp University hospital (UZA) in Belgium. The preliminary results were communicated in May 2017 at the 13th International Conference on Myasthenia Gravis and Related Disorders at the New York Academy of Science.
The final results of phase 1B, communicated in June 2018, demonstrated an excellent safety profile and called for a phase 2 efficacy clinical trial.
CuraVac is presently preparing a phase 2 efficacy clinical trial with a more potent formulation of the MG Therapeutic Vaccine: CV-MG02.
- In 2009, the human formulation of the MG vaccine is manufactured following GLP and GMP guidelines.
The myasthenia gravis Therapeutic Vaccine, our first vaccine, was granted Orphan Drug Designation in Europe by a team of independent experts of the 27 European member states.
- In 2011, the MG therapeutic vaccine was granted Orphan Drug Designation in the USA by the FDA
They didn’t know it was impossible so they did it